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Summary 
Aldose reductase, (AKR1B1), the key enzyme of the polyol pathway, plays a crucial role in the 
development of long term complications affecting diabetic patients. Nevertheless, the expedience of 
inhibiting this enzyme to treat diabetic complications has failed, due to the emergence of side effects 
from compounds under development. Actually, AKR1B1 is a Janus-faced enzyme which, besides 
ruling the polyol pathway, takes part to the antioxidant defence mechanism of the body. In this work 
we report the evidence that a class of compounds, characterized by a pyrazolo[1,5-a]pyrimidine core 
and a ionisable fragment, modulates differently the catalytic activity of the enzyme, depending on the 
presence of specific substrates like sugar, toxic aldehydes and glutathione conjugates of toxic 
aldehydes. The study stands out as a systematic attempt to generate aldose reductase differential 
inhibitors (ARDIs), intended to target long term diabetic complications while leaving unaltered the 
detoxifying role of the enzyme. 
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Introduction 
Aldose Reductase (AKR1B1), the first enzyme of the so-called polyol pathway, is acknowledged as 
the critical checkpoint for the main pathological changes affecting over time the nervous, renal, 
cardiovascular and ocular systems of diabetic patients. Accordingly, its inhibition has been pursuing 
since decades as a useful therapeutic strategy to prevent the onset of diabetic complications (Del 
Corso et al., 2008). 
However, despite the efforts to obtain effective aldose reductase inhibitors (ARIs) (Grewal et al., 
2016), a true and widespread ARI therapy is not yet an established fact and epalrestat (Figure 1) is 
the only agent successfully marketed in Japan, India and China for the treatment of diabetic 
neuropathy (Li et al., 2016). 
Products that appear to be promising during pre-clinical investigations often fail to proceed any 
further, showing uncertain results in clinical trials with humans or even leading to adverse side effects. 
These latter, in particular, have been recently correlated to the complex physiological role played by 
the enzyme (Alexiou et al., 2009). 
Actually, besides ruling the polyol pathway, AKR1B1 takes part to the antioxidant defence 
mechanisms of the body, being highly efficient in reducing toxic aldehydes, including 4-hydroxy-
2,3-nonenal (HNE), arising in large quantities from pathological conditions connected with oxidative 
stress (Srivastava et al., 1999). At the same time, AKR1B1 catalyses the reduction of glutathione 
conjugates of unsaturated aldehydes, showing in most cases a catalytic efficiency higher than that 
displayed against the parent free aldehyde. In this regard, special appears the case of the 3-
glutathionyl-4-hydroxynonanal (GS-HNE), whose reduction product 3-glutathionyl-
dihydroxynonane (GSDHN), was shown to be responsible for cytotoxicity through activation of the 
NF-κB signalling pathways, thus further muddling up the physiological role of this enzyme (Ramana 
et al., 2010; Ramana et al., 2011). 
Due to this Janus-faced nature, the expedience of inhibiting AKR1B1 to prevent and treat long-term 
diabetic complications has been debated for long and remains controversial. 
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To overcome the deadlock, we recently launched the concept of Aldose Reductase Differential 
Inhibitors (ARDIs) as a novel class of compounds able to selectively inhibit the catalytic activity of 
the enzyme depending on the specific substrates is going to be transformed (Del Corso et al., 2013). 
This approach, which may be in principle adopted for any enzyme able to act on different substrates 
(Cappiello et al., 2014), appears truly tailored for AKR1B1 which, besides being an aspecific enzyme, 
is also not permissive (Balestri et al., 2017). 
Differently from ARIs developed till now, characterized by high but unspecific binding affinity 
against the target enzyme, ARDIs should show a differential intra-site binding affinity, being able to 
inhibit the catalytic activity of AKR1B1 against glucose and GS-alkanals while leaving unaltered, or, 
in any case less affected, the reductive activity of the enzyme towards toxic hydrophobic aldehydes. 
Accordingly, using an ARDI, it is possible in principle to prevent hyperglycemia-induced cell injury 
without affecting the antioxidant defense. 
When thinking to differential inhibition, the choice of the substrate to be used for in vitro studies is 
not a trivial task. In this regard, on the bases of the peculiar non hyperbolic inhibition exerted on the 
enzyme by aldose hemiacetals (Balestri et al., 2015a), D,L glyceraldehyde usually adopted for 
inhibition studies becomes rather inadequate as a mimicking aldoses substrate. Thus when the aim of 
the test is to evaluate a differential inhibition, different physiological substrates as glucose or 
structurally related molecules (Balestri et al., 2015b), HNE and GS-HNE, chosen as examples of lipid 
aldehydes and glutathionyl-aldehyde adducts metabolized by the enzyme, respectively, should be 
used. 
Screening an in house collection of previously developed compounds, characterized by different but 
customary pharmacophoric elements for AKR1B1 molecular recognition like the hydantoin ring (Da 
Settimo et al., 2005), the phenolic fragment (La Motta et al., 2007) and the carboxylic moiety (Da 
Settimo et al., 2001; Da Settimo et al., 2005; La Motta et al., 2008; Cosconati et al., 2009), we 
identified the 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylic acid 5a (Figure 1) as a 
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promising ARDI, being able to intervene on glucose and GS-HNE reduction, catalysed by AKR1B1 
from bovine lens, more efficiently than on HNE reduction (Del Corso et al., 2013). 
With this in mind, and aiming to develop a class of effective ARDIs, we undertook the synthesis of a 
number of pyrazolopyrimidine derivatives and investigated their functional efficacy on the L-idose, 
HNE and GS-HNE reduction catalysed by the human recombinant enzyme, hAKR1B1.  
 
Results and Discussion 
Moving from the lead, 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylic acid (5a, Figure 
SI-1), identified as a promising ARDI towards the bovine lens enzyme (Del Corso et al., 2013), we 
synthesized a number of parent derivatives characterized by suitable substituents in position 4 of the 
heterocyclic core, to verify the influence of electron-withdrawal, electron-release and steric bulk on 
the differential intra-site binding affinity of the compounds. In vitro inhibitory tests on the synthesized 
compounds were firstly carried out exploiting L-idose as the substrate, chosen as a viable alternative 
to the physiologically relevant D-glucose. Actually, although similar in terms of structural 
rearrangement, the C-5 epimer of D-glucose turns out to be more useful to investigate the activity of 
the enzyme, as it offers a significantly higher concentration of the free aldehyde form when compared 
to the parent compound (Balestri et al., 2015b). 
While 5a exhibited an IC50 value of approximately 0.5 mM and 5b,c were devoid of any appreciable 
inhibitory action on hAKR1B1 (IC50 > 1 mM), the IC50 values of all the other molecules in inhibiting 
L-idose reduction were of the same order of magnitude, ranging from approximately 60 M to 200 
M. Afterward, focusing on the most active compounds (5a,d-j,l, Figure SI-1), the same assays were 
repeated using HNE as the substrate, to investigate their ARDI efficacy. The resulting differential 
inhibitory activity between L-idose and HNE reduction (DI, %) is shown in Figure 1. 
It is noteworthy that 5a, which inspired the ARDI library being a promising differential inhibitor 
when tested on the bovine lens enzyme (Del Corso et al., 2013), in the case of the human recombinant 
enzyme used in the present study shows a reduced inhibitory activity and doesn’t exhibit any 
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differential inhibitory action between L-idose and HNE reduction. Even though disappointing at the 
first glance, the observed activity is not a peculiar event, being well documented that AKR1B1 from 
different sources is possibly differently targeted by inhibitory molecules, with the human placental 
enzyme appearing as the less susceptible to inhibition (Kador et al., 1980; Morjana et al., 1989; Kador 
et al.; 1985; Lee et al.; 2010). 
In this respect, it is well conceivable that, considering the peculiar structural restrictions required for 
a molecule to act as an ARDI, differences in differential inhibition susceptibility between different 
enzyme forms have certainly more chances to take place. In any case, moving from 5a, suitable 
decoration of the pyrazolopyrimidine scaffold made it possible to recover ARDIs features, as shown 
in Figure 1. 
In particular, the presence of a p-chloro atom on the 4-benzyl ring leads to an appreciable result and 
5e, showing a DI value of 16%, turns out to be the best differential inhibitor of the whole series. 
Changing the less bulky, more electron-attracting chloro atom into the bulkier, less electron-attracting 
bromine one, as in 5f, halved the DI value (DI: 8.44%), and the insertion of the even bulkier 
trifluoromethyl group carried out the negative trend, as 5g showed a DI value of 2.6%. Finally, 5h, 
showing a DI value of 1.4% and featuring the ortho-fluoro para-bromo substitution pattern typical of 
known ARIs such as ponalrestat, ranirestat, and minalrestat, turned out to be the less effective among 
this subseries. 
Insertion of the electron-donating methyl group in the same position of the 4-benzyl ring retains a 
significant differential profile of inhibition (5i, DI: 11.0%), and the same was also true when the 
pendant phenyl ring was replaced by the bulkier naphthalene core (5j, DI: 11.3%). On the contrary, 
the presence of a methylene spacer between the main pyrazolopyrimidine liphophilic area and the 
additional aromatic ring in position 4, as in 5l, turned upside down the ADRI profile, as the compound 
rather preferentially blocks hAKR1B1, even though slightly, when processing HNE instead of L-
idose (DI: -4.03%). 
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Classical powerful ARIs like epalrestat and sorbinil were also tested as ARDIs. However, as reported 
in Figure 1, their differential inhibitory ability appears negligible. This result clearly demonstrates 
that structural requirements defined to date to obtain potent ARIs are not helpful in ARDIs’ design 
and development, and novel pharmacophoric elements must be unveiled to get to effective and potent 
differential derivatives. 
The inhibitory profile of the most effective ARDI (5e) and of a compound (5g), displaying a 
comparable inhibitory power but a rather modest differential inhibitory ability, was furthered. Besides 
being differentially active between L-idose and HNE reduction, 5e turned out to exert its inhibitory 
action also toward the reduction of GS-HNE, thus proving to fulfil thoroughly the functional 
requirements of an ARDI. The inhibition curves referring to the three substrates, reported in Figure 
2A, show that the reduction of L-idose and GS-HNE is similarly affected by the inhibitor and that the 
effect is more pronounced than that on HNE reduction. This is not the case of 5g (Figure 2B) which 
inhibits AKR1B1 irrespectively of the used substrate. The lack of any differential inhibitory action 
exerted by epalrestat and sorbinil towards the reduction of all the three adopted substrates is again 
clearly evident in Figure 2C, in which the dose/effect response for the two classical ARIs are also 
reported. The emerging IC50 values related to L-idose, HNE and GS-HNE reduction (Table 1) are 
consistent with a differential inhibitory action exerted only by 5e.  
To unveil the pattern of interaction with the target enzyme, a detailed kinetic analysis of the inhibition 
action of 5e was accomplished, using as negative controls for differential action 5g, displaying a 
rather comparable IC50 to 5e, and the powerful ARIs epalrestat and sorbinil. Results reported in 
Figures SI-1, SI-2, SI-3 and SI-4 allow to determine the inhibition models of action and the relative 
apparent dissociation constants for the binary enzyme/inhibitor complexes (𝐾𝑖
(𝑎𝑝𝑝)
) and for the 
ternary enzyme/substrate/inhibitor complexes (𝐾𝑖
′(𝑎𝑝𝑝)
) with respect to the different substrates. 
For both inhibitors 5e and 5g, it appears a significant preferential targeting of the free enzyme 
(𝐾𝑖
′(𝑎𝑝𝑝)
𝐾𝑖
(𝑎𝑝𝑝)⁄ > 1) at an extent that the inhibitory action become very close to a competitive 
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inhibition, as for 5e acting on GS-HNE reduction and 5g acting on HNE reduction. The measured 
𝐾𝑖
(𝑎𝑝𝑝)
 values (Table 2), especially for 5e, appears affected by the nature of the substrate undergoing 
reduction. In this regard, 5e seems to target the free enzyme more efficiently on L-idose and GS-HNE 
reduction, approximately two fold and four fold respectively, with respect to the HNE reduction; an 
evidence that may be invoked as the basis of the observed differential inhibitory action of this 
compound.  
On the contrary, the apparent Ki values of 5g are rather similar for all the three tested substrates. The 
same occurs for epalrestat and sorbinil, which display a mixed type of inhibition and an uncompetitive 
type of inhibition, respectively. As shown in Figures SI-3 and SI-4, the targeting of these powerful 
inhibitors to hAKR1B1 appears to occur irrespectively of the substrate undergoing reduction.  
It is important to point out that the absolute values of the inhibition constants reported in Table 2, for 
5e and 5g, necessarily obtained in the presence of DMSO, must be corrected taking into account the 
differential inhibition displayed by DMSO on the L-idose and HNE reduction catalyzed by hAKR1B1 
(Misuri et al., 2017). In particular, the apparent kinetic constants for the tested compounds should be 
divided for a factor generally defined as {1 + ([𝐷𝑀𝑆𝑂] 𝐾𝐷𝑀𝑆𝑂⁄ )}, in which [DMSO] refers to the 
concentration of DMSO present in the assay and KDMSO refer to the specific dissociations constants 
measured for DMSO either acting as competitive inhibitor of L-idose reduction or acting as mixed 
type inhibitor of the HNE reduction. Thus, for L-idose reduction, only the 𝐾𝑖
(𝑎𝑝𝑝)
value will be 
reduced by factor of 1.85, while the 𝐾𝑖
(𝑎𝑝𝑝)
and 𝐾𝑖
′(𝑎𝑝𝑝)
values measured when HNE was used as 
substrate, will be reduced by a factor of 1.75 and 1.53, respectively. No correction is required for the 
apparent inhibition constant referring to GS-HNE reduction, being DMSO ineffective on the 
reduction of this substrate (Misuri et al., 2017). With such an approach, the competitive inhibitory 
efficiency of 5e towards L-idose and GS-HNE reduction appear to be expressed by essentially the 
same Ki value (67 ± 4 µM and 70 ±16 µM, respectively) which is less than one half of the Ki value 
measured for HNE reduction. 
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Significance 
In this work we presented a series of pyrazolo[1,5-a]pyrimidine derivatives, developed as aldose 
reductase differential inhibitors (ARDIs). Among the synthesized compounds, derivative 5e, 4-(4-
chlorobenzyl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylic acid (Figure 1), emerged 
as a viable lead, proving to exert its inhibition toward the catalytic activity of hAKR1B1 with a 
preferential action against both L-idose and GS-HNE with respect to HNE. It clearly represents an 
original compound which, differently from traditional ARIs developed to date, is intended to target 
long term diabetic complications while leaving unaltered the detoxifying role of the enzyme. Further 
studies in animal models will prove its robustness as prototypical drug candidate, exploitable to 
prevent the onset and progression of hyperglycemia-induced complication without the emergence of 
the adverse side effects commonly shown by known ARIs. 
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Main Figures and Tables Titles and Legends 
Figure 1. Differential Inhibition of pyrazolo[1,5-a]pyrimidine derivatives, epalrestat and sorbinil on 
hAKR1B1. 
4-Substituted-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives, 5a,d-j,l, were tested 
as differential inhibitors at the concentration of 70 µM using either 0.8 mM L-idose or 0.04 
mM HNE as the substrates, in the presence of 8 mU of purified hAKRB1. Bars (differential 
inhibition, DI) indicate the difference between the percentage inhibition observed using L-
idose as the substrate and the percentage inhibition using HNE as the substrate. Values 
represent the mean from at least three independent measurement and error bars (if not visible 
are within the symbol size) refer to the standard deviation of the mean. Epalrestat (epa) and 
sorbinil (sorb), adopted as negative controls differential inhibitors, were used at a 
concentration of 0.1 µM and 1.0 µM, respectively. 
 
Figure 2. Inhibition effectiveness of compounds 5e, 5g, epalrestat and sorbinil on the hAKR1B1-
catalyzed reduction of the following substrates: L-idose (0.6 mM, diamonds), HNE (0.04 mM, 
circles) and GS-HNE (0.04 mM, triangles). 
(A) The enzyme activity in the presence of compound 5e was determined at the indicated inhibitor 
concentrations. Values represent the mean from at least three independent measurement and 
error bars (if not visible are within the symbol size) refer to the standard deviation of the mean. 
(B) The enzyme activity in the presence of compound 5g was determined at the indicated inhibitor 
concentrations. Values represent the mean from at least three independent measurement and 
error bars (if not visible are within the symbol size) refer to the standard deviation of the mean. 
(C) The enzyme activity in the presence of epalrestat (open symbols) and sorbinil (closed 
symbols) was determined at the indicated inhibitor concentrations. Values represent the mean 
from at least three independent measurement and error bars (if not visible are within the 
symbol size) refer to the standard deviation of the mean. 
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Table 1. Comparison of IC50 values of 5e, 5g, sorbinil, and epalrestat for AKR1B1-dependent 
reduction of different substrates. 
 
Table 2. Inhibition kinetic parameters related to 5e, 5g, sorbinil, and epalrestat as emerging from the 
kinetic analysis of depicted in Figures SI-1 and SI-2. 
 
  
17 
 
STAR Methods 
Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to and will be fulfilled 
by the Lead Contact Concettina La Motta (concettina.lamotta@unipi.it). 
Experimental Model and Subject Details 
E. coli XL-1 Blue competent cells and E. coli BL21(DE3)pLysS cells were cultured in Luria Bertani 
(LB) broth at 37°C. 
Methods Details 
Chemistry reagents and Experimentation 
3-Aminopyrazolo, diethyl 2-(ethoxymethylene)malonate, and the suitably substituted alkyl halides, 
used to obtain the target inhibitors, were from Alfa Aesar, Aldrich and Fluka. The carboxylic acid 
derivatives, 5a-l, were synthesized as outlined in Scheme SI-1. Melting points were determined using 
a Reichert Köfler hot-stage apparatus and are uncorrected. Routine nuclear magnetic resonance 
spectra were recorded in DMSO-d6 solution on a Varian Gemini 200 spectrometer, operating at 200 
MHz, and on a Bruker 400 spectrometer, operating at 400 MHz. Evaporation was performed in vacuo 
(rotary evaporator). Analytical TLC was carried out on Merck 0.2 mm precoated silica gel aluminium 
sheets (60 F-254). Purity of the target inhibitors, 5a-l, was determined by HPLC analysis, using a 
Merck Hitachi D-7000 liquid chromatograph (UV detection at 242 nm) and a Discovery C18 column 
(250 mm x 4.6 mm, 5 μm, Supelco), with a gradient of 40% water and 60% methanol and a flow rate 
of 1.4 mL/min. All the compounds showed percent purity values ≥95%.  
Synthesis of Ethyl 7-Oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylate, 3. The 
commercially available 3-aminopyrazole 1 (1.00 mmol) was dissolved in 10 mL of glacial acetic acid. 
Diethyl ethoxymethylenemalonate 2 (0.24 mL, 1.20 mmol) was then added and the solution was 
refluxed under stirring for 2 hours (TLC analysis). After cooling at room temperature, the reaction 
mixture was treated with crushed ice and the white solid that precipitated was collected by filtration, 
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washed with water and purified by recrystallization from MeOH (yield: 95%). P.f.: 295 °C. 1H-NMR 
(, DMSO-d6): 1.30 (t, 3H), 4.00 (s, 1H), 4.20 (q, 2H), 6.33 (d, 1H), 7.50 (d, 1H), 8.33 (s, 1H). 
General Procedure for the Synthesis of Ethyl 4-Substituted-7-oxo-4,7-dihydropyrazolo[1,5-
a]pyrimidine-6-carboxylate Derivatives, 4a-l. The appropriate alkyl halide (1.20 mmol) was added 
to an ice-cooled solution of ethyl 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylate 3 (1.00 
mmol) and K2CO3 (1.20 mmol) in dry DMF. After addition, the reaction mixture was heated at T=90 
°C under stirring until the disappearance of the starting material (TLC analysis). After cooling at 
room temperature, the solvent was removed under reduced pressure and the resulting crude material 
was treated with crushed ice. The white solid that precipitated was collected by filtration, washed 
with water and purified by recrystallization from the suitable solvent (Table SI-1). 
General Procedure for the Synthesis of 4-Substituted-7-oxo-4,7-dihydropyrazolo[1,5-
a]pyrimidine-6-carboxylic Acid Derivatives, 5a-l. A suspension of ethyl ester, 4a-l (1.00 mmol) in 
3 mL of 5% NaOH was heated at T=100 °C with stirring until a solution was achieved (TLC analysis). 
After cooling at room temperature, the solution was filtered and acidified with concentrated 
hydrochloric acid under ice-cooling. The white solid that precipitated was collected by filtration, 
washed with water and purified by recrystallization from the suitable solvent (Table SI-2). 
Enzymatic assay 
The activity of human placental aldose reductase (hAKR1B1) was determined at 37°C, following the 
decrease in absorbance at 340 nm due to NADPH oxidation (ε340: 6.22mM-1 cm-1) (Balestri et al., 
2016). The standard assay mixture (700 µL) contained 0.25 M sodium phosphate buffer pH 6.8, 0.4 
M ammonium sulfate, 0.5 mM EDTA, 0.18 mM NADPH, and 4.7 mM glyceraldehyde. The rate of 
NADPH oxidation in the absence of the substrate was subtracted as a blank. One unit of enzyme 
activity is the amount that catalyzes the conversion of 1 µmol of substrate/min in the above assay 
conditions. The above assay conditions were also adopted when L-idose, HNE or GSHNE (at the 
indicated concentrations) were used as substrates in inhibition studies. 
Expression and purification of AR 
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The human recombinant enzyme was expressed in E. coli cells as previously described (Balestri et 
al., 2015b). Total RNA was extracted from human placenta with TRI®Reagent, according to the 
manufacturer’s protocol. cDNA was prepared from total RNA by reverse transcription, using 200 
units of SuperScript™ III Reverse Transcriptase and 0.5 µg of an oligo-dTprimer in a mixture (50 µL 
total volume) containing 0.5 mM of each dNTP, 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol 
(DTT) and 0.1 mg/mL bovine serum albumin in 50 mM Tris–HCl, pH 8.3. After 60 min at 50°C the 
incubation mixture was used for PCR amplification or stored at -20°C. Aliquots of 1 µL of crude 
cDNA were amplified in a Bio-Rad Gene Cycler™ thermocycler, using 2.5 units of T. aquaticus 
DNA polymerase, 1 mM of each dNTP, 1 µM of each PCR primer, 50 mM KCl, 2.5 mM MgCl2 and 
0.1 mg/mL BSA in 10 mM Tris–HCl, pH 8.3, containing 0.1% (v/v) Triton X-100. At the 5’ end, we 
used the specific primer: 5’-CAT ATG GCA AGC CGT CTC CTG CTC AA-3’, corresponding to 
the sequence encoding the first six amino acids of the mature protein and containing an Nde I 
restriction site for ligation into the expression vector, which at the same time provided the ATG codon 
for an additional methionine in position 1. At the 3’ end the specific primer: 5’-GAA TTC TCA AAA 
CTC TTC ATG GAA-3’ encoded the last five amino acids, followed by a stop codon and an Eco RI 
restriction site. After an initial denaturation step at 95°C for 5 min, 35 amplification cycles were 
performed (1 min at 95°C, 30 s at 50°C, 1 min at 72°C) followed by a final step of 7 min at 72°C. An 
amplification product of about 900 bp was obtained, in agreement with the expected size (948 bp). 
The crude PCR product was ligated into a pGEM vector without further purification, using a 1:5 
(plasmid:insert) molar ratio and incubating the mixture overnight, at room temperature. After 
transformation of E. coli XL-1 Blue competent cells with the ligation product, positive colonies were 
selected by PCR using the plasmid’s primers SP6 and T7 and grown in LB/ampicillin medium. DNA 
was extracted using the Plasmid MiniPrep Kit and custom sequenced at Eurofins MWG. pGEM 
plasmid containing the appropriate sequence was digested with Nde I and Eco RI restriction enzymes 
for 2 h at 37°C and the digestion product was separated on agarose gel. The obtained fragment was 
purified from gel using QIAEX II Extraction kit and ligated into the expression vector pET30, 
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previously linearized with the same enzymes. The resulting plasmid was sequenced and shown to 
encode the mature protein. 
For expression of recombinant protein, the pET-30 vector, containing the sequence encoding 
hAKR1B1, was used to transform E. coli BL21(DE3)pLysS cells. Protein expression was induced by 
adding IPTG to a final concentration of 0.4 mM when the culture had reached a value of O.D.600=0.8. 
Cells were grown overnight at 37°C, then harvested by centrifugation and sonicated. The enzyme was 
purified from the cell extract by three chromatographic steps. In particular, the cell extract 
(approximately 0.3 g of proteins) in 0.1 M sodium phosphate buffer pH 7 containing 2 mM DTT 
(standard buffer) was applied to a column (30 x 3.5 cm) of DE-52 resin, previously equilibrated in 
standard buffer, and eluted by the same buffer at a flow rate of 15 ml/h monitoring on each fraction 
the absorbance at 280 nm until the value declined to approximately 0.5. A linear gradient of NaCl 
ranging from 0 to 120 mM in standard buffer was then applied allowing the enzyme to elute at 
approximately 100 mM salt concentration. Active fractions were pooled, concentrated and dialyzed 
against standard buffer devoid of DTT on Ultracel® 10 kDa ultrafiltration membrane, and then 
applied on a 23x3.5 cm column containing Matrex Orange A resin, previously equilibrated in standard 
buffer devoid of DTT and eluted in the same buffer at a flow-rate of 15 ml/h until the absorbance 
values at 280 nm fit the baseline. The enzyme was then eluted by supplementing the elution buffer of 
0.1 mM NADPH. The fractions containing hAR activity were pooled, supplemented of 2 mM DTT 
and concentrated on Ultracel® 10 kDa ultrafiltration membrane up to 7 mL. 
The sample was then applied on a Sephadex G-75 column (80x2.6 cm) previously equilibrated in 
standard buffer and eluted at a flow rate of 15 ml/h. 
The fractions exhibiting enzymatic activity were tested for purity by SDS-Page electrophoresis using 
the silver stain nitrate technique (Laemmli, 1970; Wray et al., 1981), pooled, and concentrated on a 
YM10 membrane. The purified human recombinant enzyme (5.3 U/mg of protein) was stored at -
80°C in standard buffer supplemented of 30% (w/v) glycerol. Immediately before use, the enzyme 
was extensively dialyzed against standard buffer devoid of DTT. 
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Protein concentration determination  
The protein concentration of enzyme preparations was evaluated by the Bradford method (Bradford, 
1976). 
Inhibition assay 
The sensitivity of AKR1B1 to inhibition was tested in the presence of inhibitors dissolved at proper 
concentrations in DMSO; the concentration of DMSO was kept constant at 1 % (v/v). IC50 values 
were determined by non linear regression analysis by fitting the data to the equation describing one 
site competition in a log-dose inhibition curve. The analysis was performed using standard statistical 
software (GraphPad Instat version 6.0, San Diego, CA). Each curve was generated using at least five 
concentrations of inhibitors and each concentration was tested at least in triplicate. 
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